Compare ATRO & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRO | AVDL |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | N/A | 1996 |
| Metric | ATRO | AVDL |
|---|---|---|
| Price | $51.13 | $21.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $61.50 | $18.38 |
| AVG Volume (30 Days) | 585.1K | ★ 2.8M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $830,601,000.00 | $248,517,000.00 |
| Revenue This Year | $9.26 | $65.47 |
| Revenue Next Year | $11.51 | $30.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.19 | ★ 79.88 |
| 52 Week Low | $15.41 | $6.38 |
| 52 Week High | $55.29 | $23.57 |
| Indicator | ATRO | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 59.01 |
| Support Level | $49.51 | $21.32 |
| Resistance Level | $55.02 | $21.62 |
| Average True Range (ATR) | 2.49 | 0.34 |
| MACD | -0.06 | -0.31 |
| Stochastic Oscillator | 54.29 | 6.90 |
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.